67853-01-4

Upstream product

• 3006-96-0 3-hydroxymethyl-benzoic acid 
• 100-44-7 benzyl chloride 
• 78767-55-2 benzyl 4-formylbenzoate 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 619-66-9 4-Carboxybenzaldehyde 

Downstream Products

• 147056-28-8 4-<<4-(benzyloxycarbonyl)phenyl>methoxy>-3,3-diethyl-2-azetidinone 
• 113100-79-1 4-bromomethylbenzoic acid benzyl ester 
• 138591-70-5 benzyl 4-(chloromethyl)benzoate 
• 1034494-08-0 4-methanesulfonyloxymethylbenzoic acid benzyl ester 
• 1196982-54-3 N-(4-aminothiophen-3-yl)-4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl]benzamide 
• 1034494-18-2 4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl] benzoic acid 
• 1034494-12-6 4-[1-(2-dimethylaminoethyl)-3-(indan-5-yl)ureidomethyl] benzoic acid benzyl ester 
• 1034494-09-1 4-(2-dimethylaminoethylaminomethyl)benzoic acid benzyl ester 
• 135835-09-5 (2R,5R)-(+)-5-(4-decyloxy-biphenyl-4'-yl-oxy-4''-carbonyl-phenylmethyl)-5-methyl-2-propyl-1,3-dioxolan-4-one 
• 135835-10-8 (2S,5R)-(+)-5-(4-decyloxy-biphenyl-4'-yl-oxy-4''-carbonyl-phenylmethyl)-5-methyl-2-propyl-1,3-dioxolan-4-one 
• 135835-05-1 (2R,5R)-(+)-2-(t-butyl)-5-(4-decyloxy-biphenyl-4'-yl-oxy-4''-carbonyl-phenylmethyl)-5-methyl-1,3-dioxolan-4-one 
• 135835-06-2 (2S,5R)-(+)-2-(t-butyl)-5-(4-decyloxy-biphenyl-4'-yl-oxy-4''-carbonyl-phenylmethyl)-5-methyl-1,3-dioxolan-4-one 
• 135835-03-9 (2R,5R)-(+)-5-(4-benzyloxycarbonyl-phenylmethyl)-2-(t-butyl)-5-methyl-1,3-dioxolan-4-one 
• 135835-04-0 (2S,5R)-(+)-5-(4-benzyloxycarbonyl-phenylmethyl)-2-(t-butyl)-5-methyl-1,3-dioxolan-4-one 

Relevant academic research and scientific papers

Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγModulator

The metabolic syndrome (MetS) is a constellation of cardiovascular and metabolic symptoms involving insulin resistance, steatohepatitis, obesity, hypertension, and heart disease, and patients suffering from MetS often require polypharmaceutical treatment.

Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-d-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1)

Sodium glucose co-transporter 1 (SGLT1) plays a dominant role in the absorption of glucose in the gut and is considered a promising target in the development of therapeutic options for postprandial hyperglycemia. Previously, we reported potent and selective SGLT1 inhibitors 1 and 2 showing efficacy in oral carbohydrate tolerance tests in diabetic rat models. In a pharmacokinetic (PK) study of 2, excessive systemic exposure to metabolites of 2 was observed, presumably due to the high permeability of its aglycone (2a). To further improve SGLT1 inhibitory activity and reduce aglycone permeability, a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-d-glycopyranoside derivatives bearing novel hydrophilic substitution groups on the phenyl ring were synthesized and their inhibitory activity toward SGLTs was evaluated. Optimized compound 14c showed an improved profile satisfying both higher activity and lower permeability of its aglycone (22f) compared with initial leads 1 and 2. Moreover, the superior efficacy of 14c in various carbohydrate tolerance tests in diabetic rat models was confirmed compared with acarbose, an α-glucosidase inhibitor (α-GI) widely used in the clinic.

NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE

The present invention relates to synthetic studies of a novel thiophenediamine derivative having a urea structure and to finding pharmaceutical actions thereof. The present invention provides a compound represented by the following general formula (1) or

NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE

The present invention relates to a study on the sy nthesis of a novel N-(2-aminophenyl)benzamide derivativ e having an urea structure and represented by the genera l formula (1); and the utilization of a pharmacological effect of the derivative. A compoun

Highly chemoselective hydrogenation method using novel finely dispersed palladium catalyst on silk-fibroin: Its preparation and activity

A palladium-fibroin complex (Pd/Fib) was prepared by soaking silk-fibroin in MeOH solution of Pd(OAc)2 for 2 days (under Ar atmosphere) - 4 days (under air). Pd(OAc)2 was gradually absorbed by fibroin and the rapid reduction of fibroin conjugated Pd(OAc)2 proceeded with MeOH as a reductant at room temperature to be the Pd(0) complex. Pd/Fib catalyzed chemoselective hydrogenation of acetylenes, olefins and azides in the presence of aromatic ketones and aldehydes, halides, N-Cbz protective groups and benzyl esters which are readily hydrogenated using Pd/C or Pd/C(en) as a catalyst.

Orally active β-lactam inhibitors of human leukocyte elastase. 2. Effect of C-4 substitution

The effect of changing the C-4 substituent of 3,3-diethyl-1- [(benzylamino)carbonyl]-2-azetidinone on inhibition of HLE and in a model of HLE-induced lung damage in hamsters was explored. Substituents at this position do not appear to interact strongly with HLE with the most potent compounds having k(obs)/[I] = 6900 M-1 s-1. However, substituents at this position had a marked effect on in vivo activity. The greatest oral activity in the lung hemorrhage assay was achieved with C-4 aryl carboxylic acid ethers (60-85% inhibition at 30 mg/kg po). Based upon the established mechanism of inhibition by these compounds, the C-4 substituent would be released, and therefore, the pharmacological potential of these C-4 substituents was of considerable concern. Fortunately, compounds containing 4-hydroxybenzoic acid and 4-hydroxyphenylacetic acid ethers at C-4 were among the most active analogs. These phenolic acids are also found as urinary metabolites in healthy humans. Other heteroaryls at C-4 were also orally active in this model despite relatively modest enzyme activity.

1.3-Dioxolan-4-ones as Chiral Unit for Ferroelectric Liquid Crystals and Dopants for Induced Ferroelectric Mesophases

The synthesis, phase behaviour, spontaneous polarization and response times of a new type of ferroelectric liquid crystals and dopants (for induced ferroelectric phases) containing trisubstituted 1.3-dioxolan-4-ones as chiral unit are described.Two pairs